Thalidomide BMS® Prescription Authorisation Form (PAF)

A newly completed copy of this form MUST accompany EVERY thalidomide prescription. Completion of this information is mandatory for ALL patients. The completed form should be retained in pharmacy.

Name of Treating Hospital:	Both signatures must be present prior to dispensing
Patient Date of Birth: DD MM YYYY Patient ID Number/Initials:	thalidomide for the patient named above.
Prescriber (print):	Prescriber's declaration
Supervising Physician name (print):	As the Prescriber, I have read and understood the Healthcare Professionals' Information Pack. I confirm the information provided on this PAF is accurate,
Indication (tick): Multiple Myeloma Other If other please specify:	complete and in accordance with the requirements of the Pregnancy Prevention Programme for thalidomide. I confirm treatment has been initiated and is monitored under the supervision of a physician with expertise in managing immunomodulatory or chemotherapeutic agents.
Quantity of capsules per cycle prescribed*: * Do NOT enter number of packs	
Number of cycle(s) prescribed: 1 2 3 3	Sign Print
Please tick all boxes that apply	
Woman of non-childbearing potential	Date DD MM YYYY Bleep
Male Tick The patient has been counselled about the teratogenic risk of treatment with	Note to pharmacist – prescription must be accompanied by a Prescription Authorisation Form
thalidomide and understands the need to use a condom if involved in sexual activity with a woman of childbearing potential not using effective contraception or if their partner is pregnant (even if the patient has had a vasectomy).	Pharmacist's declaration I am satisfied that this Prescription Authorisation Form has been completed fully and that I have read and understood the Healthcare Professionals'
Note to pharmacist – do not dispense unless ticked and, for a male, Y selected	Information Pack. For women of childbearing potential, dispensing will be taking place within 7 days of the date of prescription. I am dispensing no
Woman of childbearing potential	more than a 4-week supply to women of childbearing potential and 12 weeks for males and women of non-childbearing potential.
The patient has been counselled about the teratogenic risk of treatment, the need to avoid pregnancy, and has been on effective method of contraception for at least 4 weeks or committed to absolute and continuous abstinence	Sign Print
confirmed on a monthly basis.	Date DD MM YYYY Bleep
Date of last negative pregnancy test:	Name and postcode of
Note to pharmacist – do not dispense unless ticked, Y is selected for counselling and a negative test has been conducted within 3 days prior of the prescription date and dispensing is taking place within 7 days of the prescription date.	dispensing pharmacy

Date of preparation of text: April 2023 Approved by HPRA: November 2023